Correspondence 0001193125-24-057765 from enGene Therapeutics Inc. (ENGN)
enGene Therapeutics Inc.
Date: March 4, 2024 · CIK: 0001980845 · Accession: 0001193125-24-057765
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275700
Letter
enGene Holdings Inc.
4868 Rue Levy, Suite 220
Saint-Laurent, QC H4R2P1
(514) 332-4888
March 4, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Ms. Tamika Sheppard & Mr. Tim Buchmiller
Re:
enGene Holdings Inc.
Registration Statement on Form S-1
Filed February 27, 2024
File No. 333-275700
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, enGene Holdings Inc. hereby requests acceleration of the effective date of the above-referenced registration statement on Form S-1, as amended, so that such registration statement may become effective at 4:00 P.M. (Washington, D.C. time) on March 5, 2023, or as soon as practicable thereafter.
The Registrant hereby authorizes Howard Kenny, of Morgan, Lewis & Bockius LLP to orally modify or withdraw this request for acceleration.
Please contact Howard Kenny of Morgan, Lewis & Bockius LLP at (212) 309-6843 or howard.kenny@morganlewis.com with any questions you may have concerning this request, and please notify him when this request for acceleration has been granted.
enGene Holdings Inc.
By:
/s/ Jason D. Hanson
Name:
Jason D. Hanson
Title:
Chief Executive Officer
Show Raw Text
CORRESP 1 filename1.htm CORRESP enGene Holdings Inc. 4868 Rue Levy, Suite 220 Saint-Laurent, QC H4R2P1 (514) 332-4888 March 4, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Tamika Sheppard & Mr. Tim Buchmiller Re: enGene Holdings Inc. Registration Statement on Form S-1 Filed February 27, 2024 File No. 333-275700 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, enGene Holdings Inc. hereby requests acceleration of the effective date of the above-referenced registration statement on Form S-1, as amended, so that such registration statement may become effective at 4:00 P.M. (Washington, D.C. time) on March 5, 2023, or as soon as practicable thereafter. The Registrant hereby authorizes Howard Kenny, of Morgan, Lewis & Bockius LLP to orally modify or withdraw this request for acceleration. Please contact Howard Kenny of Morgan, Lewis & Bockius LLP at (212) 309-6843 or howard.kenny@morganlewis.com with any questions you may have concerning this request, and please notify him when this request for acceleration has been granted. enGene Holdings Inc. By: /s/ Jason D. Hanson Name: Jason D. Hanson Title: Chief Executive Officer